SCOPE OF THE JOURNAL
The Journal of Crohn's and Colitis (JCC) is the official journal of the European Crohn's and Colitis Organisation (ECCO) and is concerned with the dissemination of knowledge on clinical, basic science and innovative methods related to Inflammatory Bowel Diseases.
Authors should observe high standards with respect to publication ethics as set out by the Commission on Publication Ethics (COPE). Falsification or fabrication of data, plagiarism, including duplicate publication of the authors’ own work without proper citation, and misappropriation of the work are all unacceptable practices. Any cases of ethical misconduct are treated very seriously and will be dealt with in accordance with the COPE guidelines.
Work on human beings that is submitted to JCC should comply with the principles laid down in the Declaration of Helsinki; Recommendations guiding physicians in biomedical research involving human subjects. Adopted by the 18th World Medical Assembly, Helsinki, Finland, June 1964, amended by the 29th World Medical Assembly, Tokyo, Japan, October 1975, the 35th World Medical Assembly, Venice, Italy, October 1983, and the 41st World Medical Assembly, Hong Kong, September 1989. The manuscript should contain a statement that the work has been approved by the appropriate ethical committees related to the institution(s) in which it was performed and that subjects gave informed consent to the work. Studies involving experiments with animals must state that their care was in accordance with institution guidelines. Patients' and volunteers' names, initials, and hospital numbers should not be used.
All authors should have been involved in the writing of the manuscript at draft and any revision stages, and have read and approved the final version. Anyone who made major contributions to the writing of the manuscript should be listed as an author (e.g. “ghost writing” is prohibited by the Journal). Any other individuals who made less substantive contributions to the study or the writing of the manuscript should be listed in the acknowledgement section. Any change in authorship (including author order) after the initial manuscript submission must be approved in writing by all authors.
Authorship and 'Umbrella' groups
Many large collaborative studies are organized under a group name which represents all the participants. All articles must have at least one named individual as author. Authors who wish to acknowledge the umbrella group from which the data originate should first list the author(s) of the article and follow this with 'on behalf of the GROUP NAME'. If necessary the names of the participants may be listed in the Acknowledgements section.
Randomised controlled trials
All randomised controlled trials submitted for publication in JCC should include a completed Consolidated Standards of Reporting Trials (CONSORT) flow chart. Please refer to the CONSORT statement website at http://www.consort-statement.org and for more information. JCC has adopted the proposal from the International Committee of Medical Journal Editors (ICMJE) which require, as a condition of consideration for publication of clinical trials, registration in a public trials registry. Trials must register at or before the onset of patient enrolment. The clinical trial registration number should be included at the end of the abstract of the article. For this purpose, a clinical trial is defined as any research project that prospectively assigns human subjects to intervention or comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Studies designed for other purposes, such as to study pharmacokinetics or major toxicity (e.g. phase I trials) would be exempt. Further information can be found at http://www.icmje.org.
By submitting your manuscript to the journal it is understood that this it is an original manuscript and is unpublished work and is not under consideration elsewhere. Plagiarism, including duplicate publication of the author’s own work, in whole or in part without proper citation is not tolerated by the journal. Manuscripts submitted to the journal may be checked for originality using anti-plagiarism software.
Conflicts of interest
At the point of submission, each author should reveal any financial interests or connections, direct or indirect, or other situations that might raise the question of bias in the work reported or the conclusions, implications, or opinions stated – including pertinent commercial or other sources of funding for the individual author(s) or for the associated department(s) or organization(s), personal relationships, or direct academic competition. When considering whether you should declare a conflicting interest or connection please consider the conflict of interest test: Is there any arrangement that would embarrass you or any of your co-authors if it was to emerge after publication and you had not declared it?
This disclosure statement should be included in the submitted manuscript file as a separate paragraph under the heading Conflict of Interest Statement.
Upon acceptance of a manuscript all authors must complete an ICMJE Conflict of Interest form and submit it via the online submission system to the Editorial Office. If an author has completed an ICMJE form for ECCO within 1 year prior to submission of this manuscript then the same ICMJE form may be used.
A standard disclosure stating conflict of interests can be downloaded here.
Note that a slightly different process applies for ECCO-originated papers (e.g. Guidelines/Consensus papers, Expert Review papers, Scientific Workshop Reports, Position statements). Please contact the Editorial Office for advice.
In its aim to foster transparency, ECCO maintains a database of potential conflicts of interests (CoI) of all individuals connected with ECCO. The CoI declaration is based on the form recommended by the International Committee of Medical Journal Editors (ICMJE). ECCO stores CoI statements at the ECCO Office for those individuals with a direct relationship with ECCO (eg, for ECCO Consensus or Guideline papers) and these are available to the public via the ECCO website (https://www.ecco-ibd.eu/about-ecco/ecco-disclosures.html). The editorial office JCC archives ICMJE forms for all authors of published papers in addition to the declaration published with the paper.
A separate heading “Authors’ contributions” should be included in the manuscript to list the contribution each author made to the manuscript—eg, literature search, figures, study design, data collection, data analysis, data interpretation, writing etc. If all authors contributed equally, please state this. This is also the location to indicate that all authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Separately from the Conflict of Interest Statement and Authors’ Contributions statement, please list in the manuscript details of all funding sources for the work in question. Authors should list any internal funding. If no specific funding has been received then this should be clearly stated; equally if data have been generated as part of the routine work of an organization, this too should be stated. Ongoing financial support for any of the authors should also be included under the Funding heading.
If a professional medical writer or similar service was involved in the origin or preparation of a manuscript and this support was funded, the source must be declared in the Funding section. Sources of funding may still be thanked in an Acknowledgements section, but should not be listed again in the Conflict of Interest Statement, unless there is an important reason for doing so. For example if the funder played any decision-making role in the research this must be stated.
Funding statements should start with: ‘This work was supported by …’
The full official funding agency name should be given. Grant numbers should be complete and accurate and provided in brackets as follows: ‘(grant number ABX CDXXXXXX)’
Multiple grant numbers should be separated by a comma as follows: ‘(grant numbers ABX CDXXXXXX, EFX GHXXXXXX)’
Agencies should be separated by a semi-colon (plus ‘and’ before the last funding agency).
Where individuals need to be specified for certain sources of funding the following text should be added after the relevant agency or grant number 'to (author initials)'.
An example is given here: ‘This work was supported by the National Institutes of Health (P50 CA098252 and CA118790 to R. B. S. R.) and the Alcohol & Education Research Council (HFY GR667789).'
Crossref Funding Data Registry
In order to meet your funding requirements authors are required to name their funding sources, or state if there are none, during the submission process. For further information on this process or to find out more about the CHORUS initiative please click here.
PEER REVIEW PROCESS
All submissions to the journal are initially reviewed by one of the Editors. At this stage manuscripts may be rejected without peer review if the editors find that they are not of high enough priority or not relevant to the journal. This fast rejection process means that authors are given a quick decision and do not need to wait for the review process.
Manuscripts that are not rejected by the editors are sent out for external peer review, usually to two independent reviewers. Based on the feedback from these reviewers and the Editors’ judgment a decision is given on the manuscript. The average time from submission to first decision is 3 weeks.
Referees and editors assess the papers using the following criteria:
· Relevance to inflammatory bowel diseases
· Novelty and originality
· Scientific and clinical impact
· Methodological quality
After peer review and editorial discussion, manuscripts can be accepted for publication in JCC, sent back to authors for revisions, or rejected.
JCC publishes responses to previously-published JCC articles as letters to the editor, subject to the normal review process. Where a response is published, the author of the original JCC article will be offered the opportunity to respond to the first response. This discussion will then be considered completed, with no further responses permitted from either author. All responses should be written in a polite and respectful tone, and OUP reserves the right to edit or refuse to publish any response that it deems do not meet this requirement.
For information about this journal's policy, please visit our Author Self-Archiving policy page.
The opinions expressed in Journal of Crohn’s and Colitis are those of the authors and contributors, and do not necessarily reflect those of the editors, the editorial board, ECCO, Oxford University Press or the organization to which the authors are affiliated.